These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 453449)

  • 41. Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment.
    Warndorff van Diepen T; Mengistu G
    Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):189-97. PubMed ID: 2410520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Close contacts with leprosy in newly diagnosed leprosy patients in a high and low endemic area: comparison between Bangladesh and Thailand.
    Richardus JH; Meima A; van Marrewijk CJ; Croft RP; Smith TC
    Int J Lepr Other Mycobact Dis; 2005 Dec; 73(4):249-57. PubMed ID: 16830634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review of leprosy cases in Benghazi, Libyan Arab Jamahiriya, 1994-98.
    Toweir AA; Chaudhary RC
    East Mediterr Health J; 2000; 6(5-6):1098-102. PubMed ID: 12197333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Active surveillance of leprosy contacts in country with low prevalence rate.
    Kai M; Maeda Y; Maeda S; Fukutomi Y; Kobayashi K; Kashiwabara Y; Makino M; Abbasi MA; Khan MZ; Shah PA
    Int J Lepr Other Mycobact Dis; 2004 Mar; 72(1):50-3. PubMed ID: 15217314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NLEP--current situation and strategy during the 11th plan period (2007-2012).
    Dhillon GP
    J Indian Med Assoc; 2006 Dec; 104(12):671-2. PubMed ID: 17474280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of Rapid Village Survey and Leprosy Elimination Campaign, detection methods in two districts of East Java, Indonesia, 1997/1998 and 1999/2000.
    Schreuder PA; Liben DS; Wahjuni S; Van Den Broek J; De Soldenhoff R
    Lepr Rev; 2002 Dec; 73(4):366-75. PubMed ID: 12549844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A field trial among leprosy patients in Nigeria with depot injections of dapsone and monoacetyldapsone.
    Pieters FA; Woonink F; Zuidema J
    Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):10-20. PubMed ID: 3373080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of leprosy control on the transmission of M. leprae: is elimination being attained?
    Richardus JH; Habbema JD
    Lepr Rev; 2007 Dec; 78(4):330-7. PubMed ID: 18309706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence survey of secondary dapsone resistance in leprosy in Kancheepuram and Tiruvannamalai control units of Tamil Nadu.
    Neelan PN; Noordeen SK; Balakrishnan S; Pandian PR
    Lepr India; 1983 Apr; 55(2):222-30. PubMed ID: 6355650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of paucibacillary leprosy patients released from control relapsing with multibacillary leprosy.
    Jesudasan K; Christian M
    Int J Lepr Other Mycobact Dis; 1985 Mar; 53(1):19-21. PubMed ID: 3998560
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens.
    Fajardo TT; Villahermosa L; Pardillo FE; Abalos RM; Burgos J; Dela Cruz E; Gelber RH
    Am J Trop Med Hyg; 2009 Aug; 81(2):330-4. PubMed ID: 19635893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical trial of DADDS in lepromatous leprosy.
    Ganapati R; Naik SS; Shah MH; Shirsat LS; Gaitonde BB
    Lepr India; 1976 Jul; 48(3):238-43. PubMed ID: 799207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of leprosy in Agra District (U.P.) India from 2001 to 20031.
    Kumar A; Girdhar A; Girdhar BK
    Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):115-21. PubMed ID: 16830654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deformity incidence in leprosy patients treated with multidrug therapy.
    Rao PS; Subramanian M; Subramanian G
    Indian J Lepr; 1994; 66(4):449-54. PubMed ID: 7714354
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. III. Neural and other impairments.
    Schreuder PA
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):170-81. PubMed ID: 9728449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
    Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
    J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of multidrug therapy on leprosy in Baroda district (Gujarat).
    Chopra NK; Agarwal JS; Pandya PG
    Indian J Lepr; 1989 Apr; 61(2):179-89. PubMed ID: 2746026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intrafamilial transmission of leprosy in Vellore Town, India.
    George R; Rao PS; Mathai R; Jacob M
    Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):550-5. PubMed ID: 8151185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.